eorthopod.com

Is it possible that some medications are not being approved because some people are non-responders versus the drug not being beneficial?

Yes, because a drug may be beneficial to a small proportion of people who are responders, present study designs may dilute results due to the non-responders. The authors of a recent study suggest the use of a study design called enriched enrolment with randomised withdrawal, EERW. In this study design, subjects are tried on a drug first, and only those who have a positive response are then randomised to study it further.

Reference: 

H.J. McQuay et al. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008. Volume 135. Pp. 217-220.

Disclaimer

The information on this website is not intended to replace the advice or care from a healthcare provider. The information on this website is compiled from a variety of sources. It may not be complete or timely. It does not cover all diseases, physical conditions, ailments, or treatments. The information should NOT be used in place of visiting with your healthcare provider, nor should you disregard the advice of your healthcare provider because of any information you obtain on this website. Discuss any activities presented in this website with your healthcare provider before engaging in the activity.